Literature DB >> 28410912

Beyond Correlations, Sensitivities, and Specificities: Case Examples of the Evaluation of Advanced Imaging in Oncology Clinical Trials and Cancer Treatment.

Frank I Lin1, Erich P Huang2, Lalitha K Shankar3.   

Abstract

Although advanced imaging is an important component of oncology clinical trials, there has not been a lot of success in advancing its use from a research perspective. One likely reason is the lack of consensus on the methodology used to study advanced imaging in trials, which results in a disconcerted research effort and produces data that are difficult to collate for use in validating the imaging components being studied. Imaging is used in cancer clinical trials for various indications, and the study design needed to evaluate the imaging in a particular indication will vary. Through case examples, this paper will discuss how advanced imaging is currently being investigated in oncology clinical trials, categorized by the potential clinical indication for the imaging tool and offer suggestions on how development should proceed to further evaluate imaging in the given indication. Available National Cancer Institute resources that can assist in this process will also be discussed. Published by Elsevier Inc.

Entities:  

Keywords:  Clinical trial; cancer imaging; study design

Mesh:

Substances:

Year:  2017        PMID: 28410912      PMCID: PMC5511062          DOI: 10.1016/j.acra.2016.11.024

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  32 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

3.  Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.

Authors:  Sally F Barrington; Wendi Qian; Edward J Somer; Antonella Franceschetto; Bruno Bagni; Eva Brun; Helén Almquist; Annika Loft; Liselotte Højgaard; Massimo Federico; Andrea Gallamini; Paul Smith; Peter Johnson; John Radford; Michael J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-27       Impact factor: 9.236

4.  Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.

Authors:  Hannah M Linden; Brenda F Kurland; Lanell M Peterson; Erin K Schubert; Julie R Gralow; Jennifer M Specht; Georgiana K Ellis; Thomas J Lawton; Robert B Livingston; Philip H Petra; Jeanne M Link; Kenneth A Krohn; David A Mankoff
Journal:  Clin Cancer Res       Date:  2011-07-12       Impact factor: 12.531

5.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Authors:  H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price
Journal:  Eur J Cancer       Date:  1999-12       Impact factor: 9.162

Review 6.  Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation:a systematic review and meta-analysis.

Authors:  W Zhu; L Xing; J Yue; X Sun; X Sun; H Zhao; J Yu
Journal:  Br J Radiol       Date:  2012-02-14       Impact factor: 3.039

7.  Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol.

Authors:  Lanell M Peterson; David A Mankoff; Thomas Lawton; Kevin Yagle; Erin K Schubert; Svetlana Stekhova; Allen Gown; Jeanne M Link; Timothy Tewson; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2008-02-20       Impact factor: 10.057

8.  Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.

Authors:  Olwen M Hahn; Cheng Yang; Milica Medved; Gregory Karczmar; Emily Kistner; Theodore Karrison; Elizabeth Manchen; Myrosia Mitchell; Mark J Ratain; Walter M Stadler
Journal:  J Clin Oncol       Date:  2008-10-01       Impact factor: 44.544

Review 9.  Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis.

Authors:  LingLing Pan; Ping Gu; Gang Huang; HuiPing Xue; ShuQi Wu
Journal:  Eur J Gastroenterol Hepatol       Date:  2009-09       Impact factor: 2.566

10.  ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI.

Authors:  Elizabeth R Gerstner; Zheng Zhang; James R Fink; Mark Muzi; Lucy Hanna; Erin Greco; Melissa Prah; Kathleen M Schmainda; Akiva Mintz; Lale Kostakoglu; Edward A Eikman; Benjamin M Ellingson; Eva-Maria Ratai; A Gregory Sorensen; Daniel P Barboriak; David A Mankoff
Journal:  Clin Cancer Res       Date:  2016-05-16       Impact factor: 12.531

View more
  2 in total

Review 1.  Beyond Correlations, Sensitivities, and Specificities: A Roadmap for Demonstrating Utility of Advanced Imaging in Oncology Treatment and Clinical Trial Design.

Authors:  Erich P Huang; Frank I Lin; Lalitha K Shankar
Journal:  Acad Radiol       Date:  2017-04-26       Impact factor: 3.173

2.  SPECT/CT imaging of chemotherapy-induced tumor apoptosis using 99mTc-labeled dendrimer-entrapped gold nanoparticles.

Authors:  Yan Xing; Jingyi Zhu; Lingzhou Zhao; Zhijuan Xiong; Yujie Li; San Wu; Gitasha Chand; Xiangyang Shi; Jinhua Zhao
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.